Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 12/20 | 0.56 |
| ▸ | PLAU | P00749 | 3/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.50 |
| ▸ | ITGAV | P06756 | 1/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25455250 | 0.96 | KLKB1 (0.61) | KLKB1PLAUITGB3ITGB1ITGAV | |
| SCHEMBL25457461 | 0.92 | KLKB1 (0.49) | KLKB1PLAUITGB3ITGB1ITGAV | |
| SCHEMBL25458309 | 0.91 | ITGB3 (0.48) | KLKB1PLAUITGB3ITGB1ITGAV | |
| SCHEMBL25457067 | 0.91 | LDLR (0.47) | KLKB1PLAUITGB3ITGB1ITGAV | |
| SCHEMBL25459306 | 0.91 | KLKB1 (0.56) | KLKB1PLAUELANE | |
| SCHEMBL25459225 | 0.90 | KLKB1 (0.48) | KLKB1PLAUITGB3ITGB1ITGAV | |
| SCHEMBL25459090 | 0.90 | KLKB1 (0.59) | KLKB1PLAUITGB3ITGB1ITGAV | |
| SCHEMBL25458170 | 0.90 | KLKB1 (0.52) | KLKB1PLAUELANE | |
| SCHEMBL25455267 | 0.89 | KLKB1 (0.61) | KLKB1PLAUELANE | |
| SCHEMBL25457239 | 0.89 | PLAU (0.49) | KLKB1PLAUITGB3ITGB1ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | QUANTUM INTELLIGENCE CORP. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | ITGB7, ITGAM, ITGA4 | KLKB1 1100/4885PLAU 793/4885ITGB3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.